• Piroxicam and Deracoxib in Canine Mammary Cancer Cells

  2026-09-04

  The reference study shows that piroxicam and deracoxib reduce viability and increase apoptosis in the CMT-U27 canine mammary carcinoma cell line, with combined treatment producing stronger effects at lower concentrations. Its value is primarily methodological and hypothesis-generating: MTT viability testing combined with flow-cytometric apoptosis and cell-cycle analysis provides a structured way to evaluate NSAID combinations without treating in vitro cytotoxicity as clinical efficacy.

• Sodium Overload and Mitochondrial Failure in NECSO

  2026-09-03

  The reference study identifies mitochondrial energy failure as the central mechanism linking TRPM4-mediated sodium influx to necrosis by sodium overload. Its findings connect mitochondrial Na+ and Ca2+ imbalance with impaired oxidative phosphorylation, ATP depletion, Na/K-ATPase failure, cell swelling, and lysis, providing a framework for interpreting sodium-driven cell injury assays.

• MAPK10–KRT16 Signaling in NSCLC Metastasis

  2026-09-03

  The reference study identifies MAPK10 as a metastasis-suppressing kinase that phosphorylates KRT16 at Ser356 and Ser397, enabling RNF213-dependent ubiquitination and proteasomal degradation. Cellular, animal, and clinical data support the MAPK10/KRT16/RNF213 axis as a mechanistic model and a candidate prognostic pathway in non-small cell lung cancer.

• Polygodial Workflows for TRPA1 Research

  2026-09-02

  Polygodial offers a chemically defined way to activate TRPA1 in calcium-imaging, sensory-neuron, and epithelial signaling experiments. This guide connects acute ion-channel measurements with Ca2+/NFAT-dependent inflammatory readouts while emphasizing practical dosing, controls, storage, and troubleshooting.

• Dibutyryl-cAMP: A Better Assay Control Strategy

  2026-09-02

  Dibutyryl-cAMP, sodium salt is more than a cAMP pathway agonist: it is a practical perturbation control for separating PKA signaling from tissue-specific biology. This article connects DBcAMP sodium salt workflow design with new lessons from tau research.

• Ceftazidime in the Resistance Translation Era

  2026-09-01

  Ceftazidime remains a strategically useful third-generation cephalosporin for Gram-negative bacterial infection research, particularly when Pseudomonas biology, β-lactamase activity, and resistance transmission must be interpreted together. This article connects its cell-wall mechanism with recent carbapenemase surveillance and provides practical guidance for translational assay design.

• Cy5 Maleimide in Condensate Imaging

  2026-09-01

  Cy5 maleimide enables site-specific protein labeling, but its value extends beyond conventional imaging. This article explains how non-sulfonated Cy5 maleimide can support charge-aware studies of α-synuclein condensates and improve interpretation of fluorescence partitioning assays.

• Penicillin G Sodium in Cell Culture Workflows

  2026-08-31

  Penicillin G Sodium provides targeted protection against susceptible bacterial contaminants while preserving the interpretability of mammalian cell assays when used with appropriate controls. This guide translates a melanoma-cell workflow into practical preparation, optimization, troubleshooting, and infection-research decisions.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-31

  A 2025 study found that naturally occurring angiotensin peptides can enhance SARS-CoV-2 spike-protein binding to host receptors, with particularly strong effects for shorter or N-terminally modified fragments. The work connects renin-angiotensin system peptide processing with a biochemical step relevant to viral entry, while its antibody-based design indicates that validation in cellular and physiological models is still needed.

• Staurosporine: Interpreting Kinase-Driven Cell Death

  2026-08-30

  Staurosporine is a broad-spectrum serine/threonine protein kinase inhibitor used to connect kinase perturbation with apoptosis and tumor biology. This article explains how to interpret its effects mechanistically, design better assays, and avoid confusing a reproducible death phenotype with pathway-specific proof.

• Ceftolozane/Tazobactam Dosing in P. aeruginosa

  2026-08-29

  Ruiz and colleagues used pharmacokinetic/pharmacodynamic simulation to test whether ceftolozane/tazobactam regimens achieve bactericidal exposure targets in Pseudomonas aeruginosa bacteremia across different levels of renal clearance. The analysis supports standard exposure for a 40% fT>MIC target but identifies 2 g of ceftolozane, administered by extended infusion, as the more reliable strategy for sustained 100% fT>MIC exposure in patients with high renal clearance.

• Carbapenemase Gene Spread in CREC: Guangdong Study

  2026-08-28

  A 2025 BMC Microbiology study combined gene localization, antimicrobial susceptibility testing, conjugation assays, mobile-element analysis, and ERIC-PCR to investigate carbapenem-resistant Enterobacter cloacae across eight teaching hospitals. Its findings indicate that plasmid-associated blaNDM-1 and highly transferable resistance determinants may connect multidrug resistance with both horizontal gene transfer and clonal dissemination.

• Apicidin Workflows for HDAC and Oocyte Assays

  2026-08-28

  Apicidin enables controlled interrogation of HDAC3-linked chromatin regulation, cancer-cell phenotypes, and reproductive toxicology. This guide connects biochemical potency with practical dosing, meiotic imaging, tumor-model context, and troubleshooting strategies.

• From Nanovesicle Mechanism to Protein Evidence

  2026-08-27

  A translational framework for converting PD-L1 nanovesicle biology into reproducible protein-level evidence using customizable lysis and assay design.

• Pitavastatin (NK-104): In Vitro Workflow Guide

  2026-08-27

  Pitavastatin (NK-104, SKU B1124) provides a defined HMG-CoA reductase inhibition workflow for cellular cholesterol-synthesis assays, with a dossier benchmark of 5.8 nM in HepG2 cells. It is best used for controlled in vitro research, including cardiovascular and atherosclerosis research, and should not be treated as clinically or in vivo validated without additional evidence.

8017 records 6/535 page Previous Next First page 上5页 678910 下5页 Last page